

Soňa Balogová

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4808994/publications.pdf>

Version: 2024-02-01

46
papers

1,730
citations

430874

18
h-index

276875

41
g-index

63
all docs

63
docs citations

63
times ranked

1851
citing authors

#	ARTICLE	IF	CITATIONS
1	Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1588-1601.	6.4	319
2	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2112-2137.	6.4	208
3	Detection of Hepatocellular Carcinoma with PET/CT: A Prospective Comparison of ¹⁸ F-Fluorocholine and ¹⁸ F-FDG in Patients with Cirrhosis or Chronic Liver Disease. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1699-1706.	5.0	183
4	A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism. <i>Medicine (United States)</i> , 2015, 94, e1701.	1.0	145
5	Is 18F-Fluorocholine-Positron Emission Tomography/Computerized Tomography a New Imaging Tool for Detecting Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4531-4536.	3.6	132
6	18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 943-966.	6.4	101
7	Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 55, 448-57.	0.7	76
8	18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1995-2004.	6.4	67
9	Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. <i>Nuclear Medicine Communications</i> , 2010, 31, 389-397.	1.1	45
10	Incidental uptake of ¹⁸ F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. <i>Radiology and Oncology</i> , 2014, 48, 228-234.	1.7	44
11	Positron emission tomography with [18F]FDOPA and [18F]FDG in the imaging of small cell lung carcinoma: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1266-1269.	6.4	37
12	Diagnosis of bone metastasis: recent comparative studies of imaging modalities. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 55, 374-410.	0.7	36
13	Prospective Comparison of FDG and FET PET/CT in Patients with Head and Neck Squamous Cell Carcinoma. <i>Molecular Imaging and Biology</i> , 2008, 10, 364-373.	2.6	33
14	Impact of FDG-PET to detect recurrence of head and neck squamous cell carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2007, 137, 647-653.	1.9	30
15	What is Currently the Best Radiopharmaceutical for the Hybrid PET/CT Detection of Recurrent Medullary Thyroid Carcinoma?. <i>Current Radiopharmaceuticals</i> , 2013, 6, 96-105.	0.8	29
16	A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. <i>Nuclear Medicine Communications</i> , 2012, 33, 757-765.	1.1	22
17	Can we achieve a radionuclide radiation dose equal to or less than that of 99mTc-hydroxymethane diphosphonate bone scintigraphy with a low-dose 18F-sodium fluoride time-of-flight PET of diagnostic quality?. <i>Nuclear Medicine Communications</i> , 2013, 34, 417-425.	1.1	21
18	18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study. <i>PLoS ONE</i> , 2018, 13, e0191487.	2.5	18

#	ARTICLE	IF	CITATIONS
19	Use of choline PET for studying hepatocellular carcinoma. <i>Clinical and Translational Imaging</i> , 2014, 2, 103-113.	2.1	17
20	Effect of Erythropoietin on Bone Marrow Uptake of 18F-Fluorocholine in Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2013, 38, 200-202.	1.3	12
21	Interference of Known or Suspected Endometriosis in Reporting FDG PET/CT Performed in Another Indication. <i>Clinical Nuclear Medicine</i> , 2022, 47, 305-313.	1.3	11
22	Whole-Body 18F-Fluorocholine (FCH) PET/CT and MRI of the Spine for Monitoring Patients With Castration-Resistant Prostate Cancer Metastatic to Bone. <i>Clinical Nuclear Medicine</i> , 2014, 39, 951-959.	1.3	10
23	Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France. <i>BMC Medical Imaging</i> , 2020, 20, 25.	2.7	10
24	Prognostic value of functional tumor burden on 68Ga-DOTATOC PET/CT in patients with pancreatic neuro-endocrine tumors. <i>Neoplasma</i> , 2019, 66, 140-148.	1.6	9
25	Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey. <i>Radiology and Oncology</i> , 2014, 48, 20-28.	1.7	8
26	Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18F-fluorodeoxyglucose on pre-treatment and on interim PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1220-1230.	6.4	7
27	Tomographie par Émission de positons et cancer de la prostate. <i>Medecine Nucleaire</i> , 2008, 32, 409-417.	0.2	6
28	Radiosynoviorthesis of acromioclavicular joint using 169Er-citrate: prospective evaluation of efficacy. <i>Nuclear Medicine Review</i> , 2018, 21, 26-31.	0.5	5
29	TEP/TDM au fluorure (18F) de sodium pour la dÉtection des mÉtastases osseuses du cancer de la prostate. Description de lâ€™Étude Fluprostick de comparaison de la TEP/TDM au fluorure (18F) de sodium Á lâ€™IRM corps entierÁdans cette indication. <i>Medecine Nucleaire</i> , 2009, 33, 388-397.	0.2	3
30	Metabolic syndrome and its effect on aortic stiffness in premenopausal women. <i>Bratislava Medical Journal</i> , 2013, 114, 279-282.	0.8	3
31	Multiple endocrine neoplasia type 1 or 4: detection of hyperfunctioning parathyroid glands with 18F-fluorocholine PET/CT, illustrative cases and pitfalls. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, . .	0.7	3
32	Évolution de la demande des examens de mÉdecine nuclÉaire pour cancer de la prostate depuis lâ€™enregistrement de la fluorocholine (18F)Á: analyse sur deux ans Á lâ€™hÉpital Tenon. <i>Medecine Nucleaire</i> , 2012, 36, 363-370.	0.2	2
33	Hepatic Cavernous Hemangioma Mimicking Metastasis of Midgut Neuroendocrine Neoplasia on 18F-Fluorodihydroxyphenylalanine PET/CT. <i>Clinical Nuclear Medicine</i> , 2022, 47, 76-78.	1.3	2
34	Controversies in the management of clinical stage I testicular seminoma. <i>Central European Journal of Urology</i> , 2016, 69, 35-9.	0.3	2
35	TEP/TDM Á la fluoromÉthylcholine-(18F) dans lâ€™imagerie de la rÉcidence du cancer de la prostateÁ: jalons pour un PHRC national. <i>Medecine Nucleaire</i> , 2007, 31, 338-344.	0.2	1
36	Tomographie dÉmission de positons et radiopharmaceutiques spÉcifiques en oncologieÁ: exemples dÉapplication. <i>Medecine Nucleaire</i> , 2009, 33, 152-160.	0.2	1

#	ARTICLE	IF	CITATIONS
37	Signification dâ€™une hyperfixation prostatique du fluorodâ€™soxyglucose (18F) chez un patient sans antâ€™câ€™dent de cancer de la prostate. Cas cliniques, revue et mâ€™ta-analyse de la littâ€™ature. Medecine Nucleaire, 2014, 38, 266-274.	0.2	1
38	Strengths and limitations of using 18fluorine-fluorodihydroxyphenylalanine PET/CT for congenital hyperinsulinism. Expert Review of Endocrinology and Metabolism, 2014, 9, 477-485.	2.4	1
39	Stage I testicular seminoma risk-adapted therapeutic management. Neoplasma, 2021, 68, 613-620.	1.6	1
40	Registered and potential indications of FDG PET/CT in breast carcinoma. Archive of Oncology, 2012, 20, 152-157.	0.2	0
41	Étude râ€™trospective des consâ€™quences de lâ€™administration dâ€™une prâ€™paration de FDG contenant de 5â€™ 10â€™ de fluorure (18F) libre sur lâ€™imagerie TEP/TDM de lâ€™os sain et des foyers osseux pathologiques. Comparaison avec un groupe appariâ€™ de patients ayant reâ€™u une prâ€™paration de FDG contenant moins de 5â€™ de fluorure (18F) libre. Medecine Nucleaire, 2012, 36, 371-377.	0.2	0
42	TEP/TDM au FDG et hibernome: É propos dâ€™un cas. Medecine Nucleaire, 2012, 36, 408-412.	0.2	0
43	32nd International Austrian Winter Symposium. EJNMMI Research, 2016, 6, 32.	2.5	0
44	Reply. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 172-172.	6.4	0
45	FDG and FCH PET/CT of Multiple Myeloma at Various Clinical Situations: Lesion Detection, Proposal for a Patient-Based "Summ" Score and Reproducibility of Scoring. Blood, 2018, 132, 4487-4487.	1.4	0
46	Nuclear endocrinology in the era of precision medicine. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, , .	0.7	0